Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma"

Affiliations

• ¹ BCLC Hospital Clínic Barcelona, IDIBAPS, University of Barcelona CIBERehd, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es.
• ² Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
• ³ BCLC Hospital Clínic Barcelona, IDIBAPS, University of Barcelona CIBERehd, Barcelona, Spain; BCLC Hospital Clínic Barcelona, IDIBAPS, University of Barcelona CIBERehd, Spain; Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.